SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$41.44 USD
+0.08 (0.19%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $41.70 +0.26 (0.63%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SWTX 41.44 +0.08(0.19%)
Will SWTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SWTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SWTX
SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
SWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Tops Revenue Estimates
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why
Other News for SWTX
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Springworks Therapeutics (SWTX) and SAGE Therapeutics (SAGE)
Barclays Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)
TD Cowen Remains a Buy on Springworks Therapeutics (SWTX)
Immunome: AL102 And Other Established Protein Targets Could Drive Value
SpringWorks Therapeutics (SWTX) Shares Cross Below 200 DMA